Agendia to participate in groundbreaking clinical trial for breast cancer Agendia, a world leader in molecular tumor diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch in the first of twenty research sites nearly. I-SPY 2 is an exciting and groundbreaking new clinical trial model that will help scientists quickly and efficiently check the most promising drugs in development for women with higher risk, quickly growing breast cancers-women for whom an improvement over standard treatment could dramatically switch the chances of survival http://sildenafilca.org/reviews .
The extensive research group led by Dr. Hsieh from Division of Surgery, Chang Gung Memorial Hospital-Chiayi, used the Cox proportional hazard model to analyze risk factors for failure of TIVAD and log-rank test to evaluate actuarial survival prices. Infection, thrombosis, and medical complication rates are compared among the risk factors. A total of 1348 totally implantable venous access products were implanted into the 1280 cancer sufferers in this cohort study. In this study, the experts find that raising age group, male gender, open-finished catheter and hematogenous malignancy had been significant risk factors reducing survival of TIVADs by multivariate evaluation.